Lantern Pharma Inc
LTRN
Get informed when a big investor buys or sells
+ FollowMarket Cap$19.78M
Close$
$0.68
51.4% downside
Current Fair Value
51.4% downsideOvervalued by 51.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $19.78 Million |
|---|---|
| Enterprise Value | $13.16 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.57 |
| Beta | 2.3 |
| Outstanding Shares | 12,423,174 |
Return
| Return on Equity | 532161.34% |
|---|---|
| Return on Assets | -199026.70% |
| Return on Invested Capital | -277.48% |
Valuation & Multiples
| P/E Ratio | -0.96 |
|---|---|
| PEG | -1.51 |
| Price to Sales | - |
| Price to Book Ratio | -1.39 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.11 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | -0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.35
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 23.21%▲ 4.57% |
|---|---|
| Total Invested | $12.02M▲ 318.52% |
| Investors Holding | 39▲ 6.00% |
ESG Score
No data
About Lantern Pharma Inc
13 employeesLantern Pharma (LTRN) is a clinical-stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. It leverages advances in machine learning, genomics, and artificial int...